Enochian Biosciences Inc (ENOB) Quote

$RENB News: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
Renovaro Biosciences Inc.
Thu, April 18, 2024 at 8:45 AM EDT
In this article: RENB
+5.41%

LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.

Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers.

Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission. Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence.

Under Professor Kazemier’s direction, Amsterdam University Medical Center’s Cancer Center has launched numerous pioneering research projects, substantially enriching our understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro’s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.

As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. We believe his expertise and forward-thinking approach will guide Renovaro in refining the company's strategic initiatives, including data acquisition and biomarker selection, to position Renovaro at the forefront of innovation. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.

“We are honored to have Professor Kazemier join our team,” remarked Hon Mark Dybul, MD, CEO of Renovaro. “His extraordinary achievements in medical research and visionary leadership are tremendous assets to Renovaro. With Professor Kazemier guiding our Scientific Advisory Board, we are even more confident in our global mission to revolutionize patient care through regenerative medicine.”

Expressing his excitement, Professor Kazemier shared, “I am enthusiastic about playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having witnessed its growth from inception to its current state. I am excited to further contribute to Renovaro’s groundbreaking efforts to reshape the landscape of cancer care. I believe the Cube’s potential to shift cancer patient care from diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with Renovaro’s gifted team to steer the company's research towards transformative medical innovations.”

With Professor Kazemier's appointment, Renovaro cements its status as an AI/biotech frontrunner, ready to drive significant advancements in medical science and enhance patient outcomes in the fight against cancer.

About Renovaro:

Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Biosciences with its advanced cell-gene immunotherapy company and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), Renovaro Cube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an oncologic and transplant surgeon at Erasmus University Rotterdam, The Netherlands. After a fellowship in hepatobiliary surgery and transplantation at Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was later appointed Program Leader of Liver Transplantation there. In 2012, he was appointed as a full hepatobiliary surgery and transplantation professor at Amsterdam University Medical Center. He is currently the Clinical Director and Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his research, he aims to put fundamental research to work in clinical practice as he focuses on developing biomarkers for pancreatic and bile duct cancer and investigating the added value of Artificial Intelligence in liver tumors.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.

$RENB: Top 10 Reasons to Have on your RADAR 
https://twitter.com/JediJazz22/status/1777421007134867796/photo/1

$RENB stock market is rallying $2.90 +5.07% HOD $2.93

$RENB $2.94 +5.38% Continuing bullish momentum this week.

$RENB $2.84 +2.53% Renovaro’s mission is to aim to develop definitive, long-term remission therapies for cancers and infectious diseases. https://renovarobio.com/

$RENB $2.82 GEDiCube’s award winning #AI is developing high-performance biomarker panels for 13 different cancers. GEDi Cube Intl Ltd. a London & Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB) https://axecapitalusa.com/renb/ $GDHG $NRXP $DIS

$RENB resilient @ $2.69 0.04 (1.51%) HOD $2.72 #shortsqueeze

$RENB GEDiCUBE Intl Ltd. A wholly owned subsidiary of NASDAQ: RENB announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics Renovaro Biosciences Inc. https://www.einpresswire.com/article/688313019/renovaro-biosciences-inc-collaborates-with-nvidia-partner-gedicube-for-advanced-cancer-diagnosis-nasdaq-renb

$RENB #AI Pioneer GEDiCube/ RenovaroCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine https://renovarobio.com/news/ai-pioneer-gedicube-and-biotech-innovator-renovaro-biosciences-combine-forces-to-accelerate-personalized-medicine/

$RENB $3.19 +8.50% closing the week bullish! #shortsqueeze

$RENB $3.17 open. GEDiCUBE Intl Ltd. A wholly owned subsidiary of NASDAQ: RENB announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics Renovaro Biosciences Inc. https://www.einpresswire.com/article/688313019/renovaro-biosciences-inc-collaborates-with-nvidia-partner-gedicube-for-advanced-cancer-diagnosis-nasdaq-renb @ein_news
$GRTX $JANX $ZVSA $ADN $IFBD $PUBM $SRFM $TMDX $HOLO $AKLI $BSGM

$RENB New HOD $3.05 +1.67% $RENB Great article out summarizing Renovaro Biosciences - Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
https://ir.renovarogroup.com/news/news-details/2024/Cutting-Edge-AI-Company-GEDiCube-and-Cyclomics-sign-binding-LOI-to-join-forces-and-position-themselves-at-the-forefront-of-the-global-liquid-biopsy-marketplace/default.aspx

$RENB $3.04 HOD $3.13 Renovaro Inc. (NASDAQ:RENB) shares shot up 4% during trading. The company traded as high as $3.13 and last traded at $3.04.

RENB.........................................https://stockcharts.com/h-sc/ui?s=RENB&p=W&b=5&g=0&id=p86431144783

$RENB opens higher $2.58 +11.69% #bullish

$RENB $2.50 +.29 +13.12% Weekly Chart is Bullish.

$RENB heading for $3.00's soon!

$RENB $2.38 +8.18% In early trading #TuesdayVibes

$RENB green in power hour!

$RENB $2.19 +6.07% GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace https://finance.yahoo.com/news/cutting-edge-ai-company-gedicube-142500523.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

Cyclomics has developed a groundbreaking diagnostic method for monitoring early cancer recurrence named “CyclomicsSeq”- a novel ctDNA (circulating tumor DNA is tumor-derived fragmented DNA in the bloodstream that is not associated with cells) detection assay based on Oxford Nanopore sequencing which delivers fast, low-cost, and point-of-care sequencing. In contrast to available ctDNA-based methods, “CyclomicsSeq” ensures that even a single ctDNA molecule in the blood can be detected at very high accuracy. This solution consists of a new diagnostic kit (CyclomicsSeq), which has been licensed to Oxford Nanopore (LON: ONT), an RNA/DNA next-generation sequencing platform company.

$RENB

$RENB Great volume and price action this week!

$RENB 2.15 ready to go!

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.

$RENB

Piker

$RENB Breakthrough Testing with Nvidia AI Chips, Cyclomics and GEDICube; Early Cancer Detection: Renovaro: NASDAQ: RENB



https://www.einpresswire.com/article/690522470/breakthrough-testing-with-nvidia-ai-chips-cyclomics-and-gedicube-early-cancer-detection-renovaro-nasdaq-renb via @ein_news

$RENB 2.17 ready to fall!

$RENB - Renovaro Biosciences Collaborates with NVIDIA Partner GEDiCUBE for Advanced Cancer Diagnosis: (Nasdaq: RENB) https://www.einpresswire.com/article/688313019/renovaro-biosciences-inc-collaborates-with-nvidia-partner-gedicube-for-advanced-cancer-diagnosis-nasdaq-renb via @ein_news $NVDA

$RENB $2.10 +3.96% Renovaro Inc Unleashes Impressive Growth in Q2 2024, Boosting Shareholders' Fortunes $RENB #Stockmarket #Nasdaq Renovaro Inc: A Leader in Major Pharmaceutical Preparations Renovaro Inc has been a key player in the major pharmaceutical preparations industry. https://t.co/fzyUKz3xmN

$RENB (NASDAQ: RENB), GEDICube announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company.
GEDiCube is committed to the early detection of cancer
Cyclomics’ Omni-Omic 4th generation technology, we believe, will disrupt the cancer diagnostics market and clinical practice by enabling fast and reliable results and delivering superior performance to standard radiological and physical examination alone.

https://finance.yahoo.com/news/cutting-edge-ai-company-gedicube-142500523.html

that pumper clown stuff doesn't appear to be working.

$RENB GEDiCube’s award-winning AI is developing high-performance biomarker panels for 13 different cancers.https://finance.yahoo.com/news/cutting-edge-ai-company-gedicube-142500523.html

wow! did anyone who cares not know that?

$RENB $2.32 +2.20% up in pre-market #happyTuesday

Obviously we are still a long way from where we were, but it looks as if Hindenburg is on the defensive - volume is down (relatively) and the big sell-off from retail investors and margin-accounts did not materialize. (There have to my knowledge not been any margin-accounts with Renovaro)

So where does that leave HR - to put it bluntly "they are up shit-creek without a paddle" because after have shorted more than +1 million shares at prices over 4 (and the +300K shares sold immediately after release of report) they have not been able to buy them back at expected sub 2 levels. I know danish retail investors have added close to 400,000 this week .

Hindenburg et al (they were not in this alone) - can (as they did last time) reach out to Wall Street parasites such as H.C. Wainwright and ask them to offer funding to Renovaro. Only this time I am hopefull/certain that Renovaro will find other means of raising capital - other than through the H.C.W-scumbags and the likes. (Wainwright is under investigation for facilitating naked shorting)

$RENB 2.392 +19.60% Strong move against shorts.

what findings did they dispute?

$RENB $2.05 +2.50% Great Article #nasdaq "Hit With Short Seller Report, Renovaro Biosciences Comments On Hindenburg's Opinion Piece" $RENB #shortsqueezehttps://www.benzinga.com/general/biotech/24/02/37133612/hit-with-short-seller-report-renovaro-biosciences-comments-on-hindenburgs-opinion-piece via @Benzinga

$RENB (Nasdaq: RENB) Renovaro Biosciences Inc. Collaborates with NVIDIA Partner GEDiCUBE for Advanced Cancer Diagnosis: https://www.einpresswire.com/article/688313019/renovaro-biosciences-inc-collaborates-with-nvidia-partner-gedicube-for-advanced-cancer-diagnosis-nasdaq-renb via @ein_news

$RENB - GEDiCube is focused on developing advanced diagnostic and monitoring tests that use multi-omics, integrating data from each stage of genetic expression, including genomics, epigenomics, transcriptomics, proteomics, fragmentomics, and metabolomics. As a member of the Nvidia Inception Program, the company will integrate medical imaging into its AI engine.

$RENB - GEDiCube’s platform technology deploys next-generation AI running on NVIDIA's latest chips and stacks genetic and protein expression on top of DNA mutation for accuracy in cancer detection.

And you know what they say: "Falsus in uno, falsus in omnibus".

No one will ever trust him again. And no one should.

you are right Serhat will always be a problem for Renovaro.

Of course he is not yet convicted of the murder for hire - but one or two of the other suspects have entered a plea deal - so things look pretty bleak for him. I have NO interest in defending him or his actions

For the record- if I remember correctly the science he falsified was on Covid. (that's bad enough) The results on HPV were actually positive but he decided to enhance/multiply the effect and lied about the number of test he ran. So in theory it may work given time and modifications but we will probably never know.

Good night..

after the newly imposed rules on naked shorting in the US (which you should have had long time ago- like we have in Europe)

We do have rules about naked shorting. They're called Regulation SHO, and initially became effective in early 2005. They were then amended to make them more comprehensive in 2007.

https://www.sec.gov/rules/2004/07/short-sales#:~:text=Regulation%20SHO%20defines%20ownership%20of,the%20Commission%20to%20suspend%20temporarily

And this, updated in 2022, is more digestible:

https://www.sec.gov/investor/pubs/regsho.htm

Reg SHO worked. The SEC finds mismarked tickets now and then, and punishes the perps. But "NSS" isn't a problem successful companies complain about. Usually, the real problem is toxic funders. The guys who buy promissory notes that convert at an enormous discount to market, and then dump them on the market. The notes are also known as "death spiral convertibles".

See you tomorrow!

Thanks again. That makes sense. For some reason, the SEC calls the company Enochian merged with "DanDrit", as if it were a person's name.

Whatever made Serhat do what he did, he DID do it. Tons of crimes. Even more lies. I don't think he'll be doing any more science...

I am not so certain - after the newly imposed rules on naked shorting in the US (which you should have had long time ago- like we have in Europe) naked short-sellers need to get creative .
I have received a "guide-book" on how it's done (I won't publish it - no need to make it even more known) but it's quite ingenious. One of the things you need is a clandestine listing -
Boerse Berlin actually writes that the (listed) company has no obligations towards them - so I doubt there is any communication

Anyway - its quite late here - if further questions I'll be happy to help tomorrow :)

Dandrit was formed on the pioneering research in Dendritic Cells carried out in Copenhagen way back when. I was part of the group that were involved in a listing on the Copenhagen Exchange. However we found out that the climate for start-ups at the time was not favorable. Eventually some of the other shareholders found a way to have a "backdoor" listing through Putnam Hills - a procedure that was quite common back then... The truly interesting thing is that the research is still the basis of the product showing potential to cure Pancreatic Cancer (amongst other cancers) . The product has been modified but the basic principle is (as least as I see it) still the same.
I find it hard to accept that in spite of his many many faults and obvious crimes Serhat have contributed to the modifications that made the product potent - but I take the words of Anahid Jewett (named as one of the 2% scientist in the world by Stanford) for it

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173858099

Yes, it seems hardly to have traded at all in Berlin. I think bringing it up is just an excuse from the company. A distraction.

Many thanks. What do you think about the DanDrit part of the company? Do you have any idea why a succession of companies with something to offer would want to be bought up by a company that showed the kind of spectacularly poor judgment shown by Enochian/Renovaro?

After all, Serhat Gumrukcu was its co-founder. He hired a hitman to murder someone he'd scammed. And the hitman did it. Gumrukcu is now in prison.

And yet this company still exists.